top of page
TBD Therapeutics Inc. develops breakthrough solution for the treatment of NEUROPATHIC PAIN
Investment Request to Fund Core Activities
Heading 3
In order to reach key milestones we will require:
Current first fundraising round:
At Least $ 1 M.
To be used for:
Regulatory pre-clinical development plan & the regulatory compliance pre-clinical efficacy & safety studies for Neuropathic Pain.
TBD Therapeutics would like to pursue a SAFE (Simple Agreement For Future Equity) investment agreement offering investors future equity in the company in exchange for their investment. We will consider other types of investments.
bottom of page